

Global Cervical Cancer Vaccine Market Opportunities, 2020

<https://marketpublishers.com/r/G23F3F4D9A0EN.html>

Date: December 2015

Pages: 105

Price: US\$ 4,000.00 (Single User License)

ID: G23F3F4D9A0EN

Abstracts

Cervical cancer is mainly caused by Human Papilloma Virus (HPV) infection transmitted via sexual contact with an HPV-infected person. Two strains of HPV that are responsible for causing cervical cancer are HPV 16 and HPV 18. Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Increasing rate of unprotected sex, especially among adolescents, across various developed as well as developing regions, is resulting in growing incidences of cervical cancer, globally. As a result, an increasing number of people, especially females in the age group of 9-26 years, are opting for cervical cancer vaccines. Moreover, reduction in the number of recommended doses of HPV immunisation from three to two, which enhances the uptake of vaccine among a large adolescent female population, is anticipated to drive the global cervical cancer market during 2015 - 2020.

According to Pharmaion report, "Global Cervical Cancer Vaccine Market Opportunities, 2020", global cervical cancer market is anticipated to cross US\$ 1.6 billion by 2020 on account of increasing immunization programs for HPV vaccination, rising prevalence of cervical cancer and favorable government initiatives to increase disease awareness. However, the unavailability of HPV vaccines in some regions of the world, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market. In 2014, the United States was the largest consumer of cervical cancer vaccines, and the country is expected to continue its dominance through 2020 owing to the launch of a nine-valent HPV vaccine, Gardasil 9, in 2014 which protects against the infection of all 9 types of HPV, as compared to Gardasil that protects against only four HPV types. Majorly, two US FDA approved HPV vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe. "Global Cervical Cancer Vaccine Market Opportunities, 2020" report elaborates following

aspects related to global cervical cancer vaccine market:

Global Cervical Cancer Vaccine Market Size, Share & Forecast

Segmental Analysis – By Region & By Company

Policy & Regulatory Landscape

Changing Market Trends & Emerging Opportunities

Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

To identify the on-going trends and anticipated growth in the next five years

To gain competitive knowledge of leading market players

To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer's specific needs

Report Methodology

The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cervical cancer vaccine producers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.

Contents

1. PRODUCT OVERVIEW

2. ANALYST VIEW

3. RESEARCH METHODOLOGY

4. GLOBAL CERVICAL CANCER PATIENT EPIDEMIOLOGY

5. GLOBAL CERVICAL CANCER VACCINE MARKET OUTLOOK

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Region (United States, European Union & ROW)

5.3. By Company (Merck & Co., Inc., GlaxoSmithKline plc & Xiamen Inovax Biotech Co., Ltd.)

6. UNITED STATES CERVICAL CANCER VACCINE MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.1.2. By Volume

6.2. Market Share & Forecast

6.2.1. By Company (Merck & Co., Inc. & GlaxoSmithKline plc)

6.3. US Cervical Cancer Patient Epidemiology

7. EUROPE CERVICAL CANCER VACCINE MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.1.2. By Volume

7.2. Market Share & Forecast

7.2.1. By Company (Sanofi Pasteur MSD & GlaxoSmithKline plc)

7.3. Europe Cervical Cancer Patient Epidemiology

8. ROW CERVICAL CANCER VACCINE MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Company (GlaxoSmithKline plc, Merck Sharpe & Dome and Xiamen Inovax Biotech Co., Ltd.)

9. MARKET DYNAMICS

9.1. Drivers

9.2. Challenges

10. MARKET TRENDS & DEVELOPMENTS

10.1. New Product Development

10.2. Patient Assistance Program

10.3. Reduced HPV Vaccine Dosage

10.4. Expanding Involvement of Pharmacists

11. COMPETITIVE LANDSCAPE

11.1. Merck & Co., Inc.

11.1.1. Company Overview

11.1.2. Regulatory Footprint: Gardasil

11.1.3. Clinical Highlights: Gardasil

11.2. GlaxoSmithKline plc

11.2.1. Company Overview

11.2.2. Regulatory Footprint: Cervarix

11.2.3. Clinical Highlights: Cervarix

11.3. Xiamen Inovax Biotech Co., Ltd.

12. STRATEGIC RECOMMENDATIONS

List Of Tables

LIST OF TABLES

- Table 1: Process of Development of Cervical Cancer after an HPV Infection
- Table 2: Global HPV Vaccines and their HPV Types
- Table 3: European Union Recommended HPV Immunization, By Country, By Age
- Table 4: Partial List of HPV Vaccination Practices across European Union
- Table 5: Cervarix and Gardasil Prices offered by GAVI, By Dose, By Year
- Table 6: Cervical Cancer Vaccine in Pipeline
- Table 7: Europe Two-dose HPV Vaccines Schedule Marketing Authorization, By Year, By Age Group
- Table 8: Countries with Regulatory Approval of Gardasil
- Table 9: Key Results from Phase III Trials of Gardasil Vaccine
- Table 10: Key Results from Phase III Trials of Cervarix Vaccine

List Of Figures

LIST OF FIGURES

- Figure 1: Global Estimated Incidence and 5-Year Prevalence of Cancer of Cervix Uteri, By Number of Cases, 2012
- Figure 2: Estimated Incidence of Cancer of Cervix Uteri, By Region, By Number of Cases, 2012
- Figure 3: Global Cervical Cancer Vaccine Market Size, By Value, 2010-2020F (USD Million)
- Figure 4: Global Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
- Figure 5: Global Cervical Cancer Vaccine Market Share, By Company, By Volume, 2010-2020F
- Figure 6: United States Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume ('000 Doses), 2010-2020F
- Figure 7: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2012
- Figure 8: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2014
- Figure 9: United States Gardasil and Cervarix Vaccine for Children, Average Selling Price (ASP), 2010-2014, (USD/Dose)
- Figure 10: United States Gardasil and Cervarix Vaccine for Adults Average Selling Price (ASP), 2010-2014, (USD/Dose)
- Figure 11: United States Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
- Figure 12: United States High School Female Students Sexual Dating Violence, By Percentage, By Grade, 2013
- Figure 13: United States Estimated Incidence of Cervix Uteri Cancer and Mortality, By Number of Cases, 2012, 2015E & 2020F
- Figure 14: European Union Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume ('000 Doses), 2010-2020F
- Figure 15: Germany Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
- Figure 16: Germany Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
- Figure 17: Italy Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
- Figure 18: Italy Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
- Figure 19: France Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F

Figure 20: France Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence

Figure 21: United Kingdom Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F

Figure 22: United Kingdom Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence and 5-year Prevalence

Figure 23: European Union Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F

Figure 24: European Union Cervix Uteri Cancer Incidence and Mortality, By Number of Cases, 2012, 2015E & 2020F

Figure 25: Rest of the World Cervical Cancer Vaccine Market Size, By Value (USD Million), 2010-2020F

Figure 26: Japan Major Events Related to HPV Vaccines, 2010-2013

Figure 27: Japan Major Events Related to HPV Vaccines, 2013-2015

Figure 28: Australia HPV 3 Dose Vaccine Coverage for Females of Age 15 years, By State, By Number, 2014

Figure 29: Australia HPV 3-Dose Vaccine Coverage for Females of Age 15 years, By State, By Percentage, 2012-14

Figure 30: ROW Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F

Figure 31: Middle East and North Africa Estimated Incidence of Cancer of Cervix Uteri, By Number of Cases, 2012, 2015E & 2020F

COMPANIES MENTIONED

1. Merck & Co., Inc.
2. GlaxoSmithKline plc
3. Xiamen Inovax Biotech Co., Ltd.

I would like to order

Product name: Global Cervical Cancer Vaccine Market Opportunities, 2020

Product link: <https://marketpublishers.com/r/G23F3F4D9A0EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G23F3F4D9A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970